原発性アルドステロン症患者におけるバクスドロスタットの有効性と安全性を評価する研究

基本情報

NCT ID

NCT07007793

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

180

治験依頼者名

AstraZeneca

概要

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood Pressure (SBP) and achieving normalization of the Renin Angiotensin Aldosterone System (RAAS) in approximately 180 participants ≥ 18 years of age with Primary Aldosteronism (PA), with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. Baxdrostat (or placebo) will be administered once daily, up-titrated after 2 weeks based on clinical response and tolerability. The study is planned to be conducted globally in approximately 90 study centres and 12 countries.

対象疾患

介入

依頼者（Sponsor）